Search results
Showing 91 to 105 of 214 results for arthritis
This guideline covers assessing all chronic pain (chronic primary pain, chronic secondary pain, or both) and managing chronic primary pain in people aged 16 years and over. Chronic primary pain is pain with no clear underlying cause, or pain (or its impact) that is out of proportion to any observable injury or disease.
Discontinued Reference number: GID-TAG402
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]
In development Reference number: GID-TA10598 Expected publication date: TBC
Discontinued Reference number: GID-TAG400
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]
Discontinued Reference number: GID-TAG393
Total prosthetic replacement of the temporomandibular joint (IPG500)
Evidence-based recommendations on total prosthetic replacement of the temporomandibular joint. This involves replacing the joint with an artificial one.
Canakinumab and tocilizumab for treating systemic juvenile idiopathic arthritis [ID983]
Discontinued Reference number: GID-TA11241
Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)
Discontinued Reference number: GID-TA10180
long-term prognosis of psoriasis severity, comorbidities (including psoriatic arthritis), or treatment -related adverse effects, and are...
Joint distraction for knee osteoarthritis without alignment correction (IPG529)
Evidence-based recommendations on joint distraction for knee osteoarthritis without alignment correction. This involves fixing a metal frame around the knee to take weight off the joint and encourage the cartilage to repair itself.
View recommendations for IPG529Show all sections
This quality standard covers diagnosing, assessing and managing osteoarthritis in adults aged over 16. It includes treatment and support, and referral for joint surgery. It describes high-quality care in priority areas for improvement.
View quality statements for QS87Show all sections
Sections for QS87
- Quality statements
- Quality statement 1: Diagnosis
- Quality statement 2: Assessment at diagnosis
- Quality statement 3: Information and support
- Quality statement 4: Therapeutic exercise
- Quality statement 5: Weight loss
- Quality statement 6: Follow-up
- Quality statement 7: Core treatments before referral for consideration of joint surgery
Otilimab for treating moderate to severe rheumatoid arthritis [ID6171]
Discontinued Reference number: GID-TA11108
Evidence-based recommendations on shoulder resurfacing arthroplasty. This involves reshaping the upper arm bone and placing an artificial shoulder joint onto it.
View recommendations for IPG354Show all sections
Sections for IPG354
The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.
Systemic juvenile idiopathic arthritis: canakinumab (ESNM36)
This evidence summary has been withdrawn. An NHS England clinical commissioning policy statement on biologic therapies for the treatment of juvenile idiopathic arthritis is available.